Can Fite Biofarma (Can Fite Biofarma) Pre-Tax Income

: $-7.63 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Can Fite Biofarma's pretax income for the three months ended in Dec. 2023 was $-1.65 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.63 Mil. Can Fite Biofarma's pretax margin was -1,065.81%.

During the past 13 years, Can Fite Biofarma's highest Pretax Margin was -171.91%. The lowest was -5066.83%. And the median was -1255.88%.

Can Fite Biofarma Pre-Tax Income Historical Data

The historical data trend for Can Fite Biofarma's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-12.63

-14.44

-12.62

-10.17

-7.63

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-3.02	-2.55	-1.67	-1.76	-1.65

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Pre-Tax Income falls into.

Can Fite Biofarma Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Can Fite Biofarma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-8.195	+	0.069	+	-0.014	+	0.506	+	-1.7763568394003E-15
	=	-7.63

Can Fite Biofarma's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.834	+	0	+	0	+	0	+	0.182
	=	-1.65

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.63 Mil.

Can Fite Biofarma (AMEX:CANF) Pre-Tax Income Explanation

Can Fite Biofarma's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-1.652	/	0.155
	=	-1,065.81%

During the past 13 years, Can Fite Biofarma's highest Pretax Margin was -171.91%. The lowest was -5066.83%. And the median was -1255.88%.

Can Fite Biofarma Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).